Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased to $77.93. The company has shown significant revenue growth but faces challenges in ROE and ROA.
August 28, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech has received predominantly bullish analyst ratings, with an average price target increase to $77.93. The company shows strong revenue growth but faces challenges in ROE and ROA.
The majority of analysts are bullish on Legend Biotech, with an increase in the average price target indicating positive sentiment. The company's strong revenue growth supports this outlook, although challenges in ROE and ROA may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100